Genmab is headquartered in Copenhagen, Denmark.
Genmab disclosed revenue of 3,003M USD for 2024 and 2,446M USD for 2023.
Genmab has 2,639 employees.
Genmab is a life science company.
Genmab was founded in 1999.
Genmab is an international biotechnology company using its antibody technology platform to offer bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function-enhanced antibodies, and antibody-drug conjugates. Genmab was formed in 1999 and is headquartered in Copenhagen, Denmark.
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.4/yr) | # | - | - | - | - | 1 | 1 | 2 |
| vol | $1.8B | $8.0B | $9.8B | |||||
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 2 | ||||||||
| Financial | Deals |
|---|---|
|
Goldman Sachs |
1 |
|
Morgan Stanley |
1 |
|
PJT Partners |
1 |
| Legal | Deals |
|---|---|
|
Kromann Reumert |
2 |
|
A&O Shearman |
1 |
|
Simmons & Simmons |
1 |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
